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Bacillus anthracis is innately resistant to trimethoprim (TMP), a synthetic antifolate that selectively inhibits
several bacterial dihydrofolate reductases (DHFRs) but not human DHFR. Previously, we were able to confirm
that TMP resistance in B. anthracis (MIC > 2,048 g/ml) is due to the lack of selectivity of TMP for the B.
anthracis DHFR (E. W. Barrow, P. C. Bourne, and W. W. Barrow, Antimicrob. Agents Chemother. 48:4643–
4649, 2004). In this investigation, 24 2,4-diaminopyrimidine derivatives, representing a class of compounds
with dihydrophthalazine side chains, were screened for their in vitro effects on B. anthracis Sterne and their
selectivities for the B. anthracis DHFR. MICs were obtained by a colorimetric (Alamar blue) broth microdi-
lution assay. Purified human recombinant DHFR (rDHFR) and B. anthracis rDHFR were used in a validated
enzyme assay to determine the 50% inhibitory concentrations (IC50s) and the selectivity ratios of the deriva-
tives. The MICs ranged from 12.8 to 128 g/ml for all but nine compounds, for which the MICs were >128
g/ml. The IC50 values for B. anthracis rDHFR ranged from 46 to 600 nM, whereas the IC50 values for human
rDHFR were >16,000 nM. This is the first report on the in vitro inhibitory actions of this class of antifolates
against TMP-resistant B. anthracis isolates. The selective inhibition of B. anthracis rDHFR and the in vitro
activity against B. anthracis demonstrate that members of this class of compounds have the potential to be
developed into clinically important therapeutic choices for the treatment of infections caused by TMP-resistant
bacteria, such as B. anthracis.
The increasing incidence of antibiotic-resistant pathogens is
a significant threat because of the inability to effectively treat
certain infectious diseases. The development of new and effi-
cient antibiotics is an important aspect in dealing with the
challenge presented by antibiotic resistance.
Anthrax, although primarily a disease of herbivorous ani-
mals, can affect humans as a cutaneous, gastrointestinal, or
respiratory disease (12). Respiratory anthrax is a rare disease
but difficult to diagnose and fatal in almost all cases unless the
patient is treated with antibiotics. The etiological agent of
anthrax, Bacillus anthracis, is one of the category A priority
pathogens on the list of the National Institute of Allergy and
Infectious Diseases (NIAID) division of the National Institutes
of Health (NIH). One of the objectives of NIH is to develop
antimicrobics for use in the treatment of anthrax.
Several antimicrobics, including ciprofloxacin and doxycy-
cline, are approved and available for the treatment of anthrax
(14). However, resistance to several of these compounds has
been documented (5, 6, 9, 18, 19, 23). In addition, penicillin-
resistant B. anthracis-like bacteria have been isolated from wild
nonhuman primates who died of an anthrax-like disease in
Côte d’Ivoire (16).
Both dihydrofolate reductase (DHFR) and dihydropteroate
synthase (DHPS) are proven targets for antimicrobial drugs.
They play key roles in the folate biosynthetic pathway that
generates the cofactors necessary for continued DNA and
RNA synthesis. As reported previously, trimethoprim (TMP)
and sulfonamides are not effective against B. anthracis (1, 20).
The genetic basis for TMP and sulfonamide resistance is as-
sociated with the chromosomally encoded gene for each en-
zyme target, DHFR (2) and DHPS (24), respectively. This
prompted us to pursue activities for the development of drugs
that overcome the TMP resistance of B. anthracis. Various
antifolates were screened for their in vitro activities against B.
anthracis and the enzyme target, DHFR. Initial studies with a
few of these DHFR inhibitors were reported previously (3).
Because of those results, additional derivatives were examined
for their effectiveness against B. anthracis and the enzyme
target, DHFR.
The objectives of the current study were to (i) screen addi-
tional inhibitors of B. anthracis recombinant DHFR (rDHFR)
and to determine the MICs for those that had reasonable in
vitro activities (at concentrations 128 g/ml) and (ii) assay hit
compounds to determine the 50% inhibitory concentrations
(IC50s) for the bacterial and the human enzymes to identify
specific antibacterial DHFR inhibitors.
(Parts of this research were presented at the 45th Inter-
science Conference on Antimicrobial Agents and Chemother-
apy, Washington, DC.)
MATERIALS AND METHODS
Microorganisms. B. anthracis Sterne was used for initial drug screening. This
strain was acquired from Rebecca Morton, Oklahoma State University Center
for Veterinary Health Sciences. The B. anthracis Ames strain (NR-411) was used
for confirmation of activity against a virulent strain and was obtained through the
Biodefense and Emerging Infectious Research Resources Repository, NIAID,
NIH. Work with the Ames strain was conducted in a CDC-registered and -ap-
proved biosafety level 3 laboratory, and appropriate biosafety and security reg-
ulations were used. The other strains used in this study included Enterococcus
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faecalis ATCC 29212 and Escherichia coli ATCC 25922, which were obtained
from ATCC. Upon receipt, the strains were checked for purity and stocks were
grown in an appropriate medium.
Compounds. The compounds were provided by Basilea Pharmaceutica, Basel,
Switzerland. The compounds were synthesized as described in a previous patent
(13).
MIC determinations. The MICs of the compounds for B. anthracis Sterne and
Ames were determined by an Alamar blue broth microdilution assay, as de-
scribed previously (3, 4). In the case of the B. anthracis, the final inoculum was
5.0  104 CFU/ml, equivalent in turbidity to a 0.5 McFarland standard.
Sterile solutions of test and quality control (QC) drugs were maintained at
80°C. The test compounds and the QC drug solutions were prepared at the
appropriate concentrations in cation-adjusted Mueller-Hinton broth (Becton
Dickinson, Cockeysville, MD) (7) containing 10% Alamar blue and then ali-
quoted into 96-well plates at 100 l/well. The plates were prepared and infected
on the same day. Doxycycline at three concentrations (twofold dilutions, 1 to 0.25
g/ml) was used to determine the MIC for E. coli ATCC 29255. For plates
infected with the Sterne strain, doxycycline was used at 0.0156, 0.03125, and
0.0625 g/ml. For plates infected with the Ames strain, the doxycycline concen-
trations at twofold dilutions were 0.0156 to 0.25 g/ml. TMP-sulfamethoxazole
concentrations (twofold dilutions of TMP-sulfamethoxazole from 2/38 to 0.25/
4.75 g/ml) were used for E. faecalis ATCC 29212. Sterility control wells and
growth control wells for each agent were included in the 96-well plate.
For initial screens of the test compounds, 10-fold dilutions from 128 g/ml to
0.128 g/ml were used in triplicate columns. Two columns were infected, and the
third column served as a color control. This also allowed observation of drug
precipitation. In subsequent panels, drug concentrations were used at twofold
dilutions. The MIC for each compound was evaluated four times by using the
dilution range of 128 to 0.128 g/ml. Subsequent MIC evaluations at narrower
ranges were also conducted four times. Thus, the MIC for each compound was
evaluated eight times in total.
After 16 h incubation, the plates were allowed to equilibrate for 30 min at
room temperature before they were sealed with a sterile plate sealer (Nunc). The
plate was then read visually and spectrophotometrically in an optical microtiter
plate reader programmed to subtract the absorbance at 600 nm from that at 570
nm. The MICs are reported as the lowest drug concentrations yielding a differ-
ential absorbance of zero or less (i.e., the color remained blue). The MICs were
compared to the acceptable limits for the QC strains (see Table 3 in reference 8)
to validate drug performance and medium suitability.
For B. anthracis Ames, the drugs which had the best MICs for strain Sterne
were prepared in 96-well plates in alternating twofold dilutions to encompass
more drug concentrations. QC drugs, as well as sterility and growth control wells,
were included as described above. The plates were infected, incubated, and read
as described above.
Expression and purification of Sterne rDHFR. The strain Sterne rDHFR was
expressed in E. coli and purified as described previously (2). Fractions containing
purified enzyme were pooled and the His tag was removed by using a Novagen
thrombin cleavage kit, according to the manufacturer’s instructions. Polyacryl-
amide gel electrophoresis analysis, performed as described Laemmli (17) with
12.5% acrylamide gels, was used to confirm the cleavage of the His tag and
indicated a purity of greater than 95%.
DHFR assay. The activity for Sterne rDHFR was measured at 30°C as the
decrease in the absorbance at 340 nm over 3 min (2). The average of two or more
determinations was used to determine the IC50s.
Homology model. For the generation of the model of the B. anthracis DHFR
structure, the X-ray structure of the TMP-resistant Staphylococcus aureus DHFR
F98Y mutant (10) was chosen as a template because the enzyme of this strain
shares a relatively high degree of sequence identity (45%) with the B. anthracis
DHFR. The model was generated with the homology model module of the MOE
software package (Chemical Computing Group, Köln, Germany) by using the
AMBER 94 force field. The final model is highly similar to the structure of the
S. aureus DHFR, which is reflected in a root mean square deviation of 0.5 Å (C
atoms). The sequence used in the DHFR structure paper did not include me-
thionine at position 1 (10). In this study, we have used methionine at position 1,
and as a result, F98 is now F99 for the S. aureus F98Y mutant (Fig. 1), consistent
with the sequence for the parent S. aureus ATCC 25923 strain reported previ-
ously (11).
RESULTS
Initial screening. In the initial stages, several DHFR inhib-
itors were tested against B. anthracis Sterne, the B. anthracis
rDHFR, and the human rDHFR. Particularly good results
were obtained with four derivatives from one subclass of 2,4-
diaminopyrimidine analogues with a dihydrophthalazine side
chain (3), referred to here as type A (Table 1).
Encouraged by this finding, we tested more compounds of
type A with diverse side chains at the R1 and R2 positions. The
results for these additional derivatives are presented in Table
1, along with those for the original four hit compounds
(BAL17662, BAL16796, BAL16700, and BAL16763), which
are marked in boldface in Table 1. Eight additional derivatives
had MICs 128 g/ml, but the results are not shown in Table
1; they are discussed in the text. We chose 128 g/ml as the
upper MIC with which to conduct the subsequent IC50 evalu-
ations with the recombinant enzymes. This was primarily due
to the twofold dilution testing range that we used for the initial
screening. For compounds with MICs exceeding this value, no
IC50 determinations were performed. Additionally, all of the
compounds listed in Table 1 have very low levels of activity
against the human rDHFR.
From the initial screening, it was determined that the best
compound was BAL17662, with a MIC of 12.8 g/ml and an
IC50 for the B. anthracis rDHFR of 54 nM (Table 1). This
compound also had reduced selectivity for the human rDHFR
FIG. 1. Alignment of sequences for B. anthracis Sterne (GenBank accession number AAT40581) and the F98Y mutant of S. aureus ATCC
25923 (10). Sequence identity is indicated by residues highlighted in black, and sequence conservation is indicated by residues highlighted in gray.
Residues highlighted in red are located in the active site and are likely to influence inhibitor binding. These residues are discussed in the text in
association with the homology model.
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TABLE 1. Compounds of type A with MICs of 128 g/ml for B. anthracis Sternea






E1 -O-CH3 No substitution 444.50 128 ND ND ND
C1 -O-CH3 -CH3 458.52 64 (64) 92  3.3
e 28,000e 304
B2 -O-CH3 -CH2-CH3 472.55 32 (25.6) 96  14
e 27,000e 281
BAL17662 -O-CH3 -CH2-CH2-CH3 486.58 12.8 (16) 54  12
e 110,000  26,000f 2,037
G1 -O-CH3 -CH2-CH2-CH2-CH3 500.61 12.8 (12.8) 170  26
e 20,000e 118
C2 -O-CH3 -CH2-CH2-CH2-OH 502.58 64 (102.4) 120  9
e 25,000e 208
BAL16796 -O-CH3 544.61 128 300  4
f 813,000  31,000f 2,710
BAL16700 -O-CH3 626.30 25.6 (51.2) 46  7
f 16,000f 348
C3 -O-CH3 512.62 25.6 (12.8) 200  63
e 22,000e 110
D3 -O-CH3 526.64 12.8 (12.8) 260  6
e 19,000e 73
A3 -O-CH3 534.62 64 (51.2) 150  13
e 19,000e 127
A2 -O-CH3 550.62 128 97  21
f 23,000f 237
B3 -O-CH3 582.62 128 600  100
f 22,000f 37
BAL16763 -O-CH3 614.15 128 400  13
e 42,000e 105
E2 -OH 536.60 128 69  21f 24,000f 348
G2 619.73 32 (25.6) 170  7e 21,000e 124
a The chiral center is marked with an asterisk.
b MICs are given as the means  standard errors of the means (n 	 4).
c IC50 values are given for the B. anthracis DHFR (BaDHFR) and the human (HuDHFR) rDHFR and are means  standard errors of the mean. ND, not
determined.
d SR, selectivity ratio, which is the IC50 for human DHFR/IC50 for B. anthracis DHFR.
e n 	 3.
f n 	 2.
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(110,000 nM) and a selectivity ratio of 2,037 (Table 1). By
grouping this compound with compounds with other, similar
structures identified in the first round of testing, i.e.,
BAL16796, BAL16700, and BAL16763, it is possible to ob-
serve the effects of various substituted or unsubstituted alkyl
chains at the R2 position (compounds E1, C1, B2, BAL17662,
G1, C2, and BAL16796; Table 1). With no substitution at R2
(compound E1; Table 1), the in vitro activity is essentially lost
(MIC  128 g/ml). However, an unsubstituted alkyl chain
increases the in vitro activity, as observed with compounds C1,
B2, BAL17662, and G1 (Table 1). The optimal length of this
side chain remains to be determined. When a hydroxyl group is
added to BAL17662, the MIC increases slightly and the IC50
increases about twofold (compound C2; Table 1). When a
complex substituted alkyl chain is attached (e.g., compound
BAL16796), the MIC increases even more (Table 1).
When compounds like BAL16700 and BAL16763 were com-
pared to similar compounds containing cyclic substitutions at
the R2 position (compounds C3, D3, A3, A2, and B3), various
effects were observed with this series of 2, 4-diaminopyrimidine
analogues. All of these derivatives have MICs of less than 128
g/ml and a lack of selectivity for the human rDHFR (com-
pounds C3, D3, A3, A2, and B3; Table 1). The best compound
in this series is compound D3, in which case the R2 substitution
is cyclohexane. The next best activity is observed with a phenyl
group (compound BAL16700) or a cyclopentane group (com-
pound C3) in the R2 position (Table 1). Addition of a toluene
group still maintains good activity and selectivity (compound
A3), as does the addition of a phenylmethanol group (com-
pound A2) (Table 1). However, addition of a phenol (com-
pound B1), furan (compound F1), pyridine (compound H1), or
2-phenylethanol group (compound A1) eliminates the in vitro
activity (i.e., MIC  128 g/ml) (structures not shown). Ad-
dition of a 2,4-dimethoxypyrimidine group (compound B3)
or an N,N-dimethyl-1-phenylmethanamine group (compound
BAL16763) restores reasonable activity and selectivity for the
B. anthracis rDHFR (Table 1).
Two other derivatives, not discussed above, that contained
modifications at R1 and R2 were evaluated. Compound E2,
with a hydroxyl group at R1 and a phenylmethanol group at R2,
has a MIC less than 128 g/ml and an IC50 of 69 g/ml (Table
1). Compound G2, which is similar to compound BAL16700
but with a 2
-morpholinoethoxy group at R1, has a MIC of 32
g/ml (Table 1).
Other derivatives that were not highly active in vitro (i.e.,
MICs  128 g/ml) included the indicated substitutions for R1
and R2, respectively, as follows: compound D1, hydroxyl and
phenol; compound D2, dimethoxymethyl and phenol; com-
pound F2, dimethoxymethyl and phenylmethanol; and com-
pound H2, methyl 2-methoxyacetyl and phenol.
Evaluation of B. anthracis Ames. For these evaluations, the
drug concentration ranges were customized on the basis of
previous results obtained with the Sterne strain. The MICs for
these 10 compounds are given in parentheses after the MICs
reported for the Sterne strain in Table 1. Essentially, there
were no marked differences for compounds C1, B2,
BAL17662, G1, C3, D3, A3, and G2 (Table 1). However,
compounds C2 and BAL16700 (Table 1) showed marked in-
creases in their MICs for the Ames strain. The reason for this
was not examined further.
Homology model. We have generated a model of the B.
anthracis DHFR structure to rationalize our experimental re-
sults and to subsequently optimize our inhibitors. As discussed
previously, an X-ray structure of the TMP-resistant S. aureus
F98Y DHFR mutant was selected as a template. The sequence
alignments for these two proteins are shown in Fig. 1, along
with the residues discussed here (highlighted in red). It should
be noted that the similarity of the sequence of the strain Sterne
DHFR is 100% with the sequences of the DHFRs of several
virulent strains of B. anthracis, including the Ames strain (2).
As the F99Y mutation causes TMP resistance in S. aureus (10),
it appears likely that the corresponding tyrosine is also in-
volved in the TMP resistance of B. anthracis (102Y) (Fig. 2).
As expected by the sequence similarity, the model obtained is
highly similar to the template structure, which is reflected in a
root mean square deviation of 0.5 Å for the C atoms. Also,
for the majority of the side chains in the inhibitor-binding
pocket, an almost identical position is assigned.
However, several deviations which are likely to influence the
binding of inhibitors can be observed (Fig. 2). In B. anthracis,
a methionine is located at the position of the L6 of S. aureus.
This alteration can be expected to have a negative influence on
the inhibitor affinity, since this residue contributes to the shape
of the subpocket hosting the diamino-pyrimidine moiety. The
change of D28 (in S. aureus) to a glutamate is expected to
result in a significant weakening of the inhibitor affinity (Fig.
2). A shift of the inhibitor of at least 0.5 Å is required to
maintain the hydrogen bonding. Three mutations are observed
in the proximity of the dimethoxy-phenyl moiety. The mutation
of T47 to an asparagine residue (Fig. 2) not only decreases the
size of this subpocket but also alters the donor-acceptor pat-
tern (Fig. 2). Although the mutations of Q20 to an asparagine
and especially of the mutation of S50 to an alanine (Fig. 1, and
2) are located at the edge of the binding pocket, they can be
expected to influence significantly the preference for R1 sub-
stituents, as both the shape and the hydrogen-bond donor-
acceptor pattern are considerably changed.
In contrast to the change of N57G, the mutation K30Q (Fig.
1 and 2) appears to be more relevant since it renders this
residue into a potential hydrogen-bond partner for substituents
at the R2 position. An indirect effect might be caused by the
mutation of T37 to a methionine (Fig. 1 and 2). This residue is
involved in a hydrogen-bonding pattern, which fixes the posi-
tion of R59 in the S. aureus DHFR. A weakening of this
H-bond pattern can result in an alternative conformation of
the arginine, which would significantly decrease the size of this
subpocket.
The preference for R1 and R2 substituents might also be
influenced by the mutations of H24 and K53 to arginine resi-
dues (Fig. 1). The modeled orientations of folate and TMP in
the binding pocket of the B. anthracis DHFR homology model
are shown in an electrostatic surface representation in Fig. 3.
The pteridine ring of the folate is buried inside the negatively
charged pocket, with the glutamate moiety protruding out
from the pocket, where its position is stabilized by a positively
charged surface patch formed by the side chains of arginine
residues R24, R53, and R58, together with lysine residues K34
and K111. The change of both the size and the donor and
acceptor properties of this positively charged patch that forms
the ceiling and left wall of the entrance to the folate-binding
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pocket could result in additional H-bond interactions. How-
ever, due to the high solvent exposure of these residues, this
hypothesis requires further investigation either by structure
analysis of the B. anthracis DHFR or by mutation experiments.
DISCUSSION
In 2005, we reported on a group of 2,4-diaminopyrimidine
derivatives with in vitro activities against B. anthracis Sterne
and selective activities against B. anthracis rDHFR but not
human rDHFR (3). For five of the six derivatives, the MICs
ranged from 12.5 to 128 g/ml (3). The IC50 values for the B.
anthracis rDHFR ranged from 46 to 404 nM for four com-
pounds, while the IC50 values for human rDHFR were greater
than 16,000 nM, with the best being 813,000 nM (3). To our
knowledge, this was the first such report demonstrating any
antifolate with activity against B. anthracis.
Recently, Joska and Anderson reported on several 2,4-di-
amino-5-deazapteridine and pyrimidine derivatives with in vitro
activities against Bacillus cereus (15). The most potent com-
pound was in the 2,4-diamino-5-deazapteridine group, with an
MIC50 of 1.6 g/ml (15). Using recombinant B. cereus DHFR
(which has 98% sequence identity with the B. anthracis
DHFR), the investigators were able to show IC50s ranging
from 0.27 to 252 M (i.e., 270 to 252,000 nM) (15); no com-
parative evaluation was reported for human DHFR. However,
the authors did cite previous data obtained with some of the
compounds for rat DHFR in which the IC50 was 25 M for the
best compound (22); that compound had a MIC50 of 2.6 g/ml
(15). The six pyrimidine derivatives were much less selective
for the B. cereus rDHFR, with IC50s ranging from 37 to 150
M. Apparently, none of the antifolates in the Joska and
Anderson study were evaluated against an avirulent or virulent
strain of B. anthracis (15).
In our current investigation we have extended the findings of
our previous studies with the 2,4-diaminopyrimidine group of
antifolates. Additionally, the in vitro activities of several of the
hit compounds have been confirmed with the virulent Ames
strain. The most active compounds have small, hydrophobic side
chains at positions R1 and R2 (e.g., compounds BAL17662, B2,
FIG. 2. View of the binding pocket of a modeled B. anthracis DHFR-phthalazine inhibitor complex. The highlighted amino acid side chains are
different from the amino acids in the S. aureus enzyme and are expected to influence inhibitor binding.
FIG. 3. Electrostatic surface representation of the folate-binding
pocket in the B. anthracis homology model. The surface is color coded
from negative red (Ve) to positive blue (
Ve). The binding positions of
folate and NADPH are shown as a stick representation. The modeled
binding position of TMP is shown as a magenta stick representation. The
positively charged area that forms a binding pocket for large R2 groups
can be seen clearly at the bottom. The figure was generated with the
CCP4MG program (21).
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and BAL16700; Table 1). It appears that the side chain at
position R2 should be larger than a methyl or ethyl group for
optimal activity (Table 1). A molecule without a side chain at
position R2 and a methoxy group at position R1 is inactive
against B. anthracis Sterne (e.g., compound E1; Table 1). Ad-
ducts larger than cyclohexane show reduced activities, proba-
bly because of steric problems but also because of electronic
properties (e.g., compounds A1, A2, B1, B3, and BAL16763
versus compound BAL16700; Table 1). A benzyl side chain is
well tolerated, while a pyridine leads to a loss of activity of the
molecule (e.g., compound H1 versus compound BAL16700;
Table 1). Compounds with a methoxy group at position R1
have antibacterial activities similar to that of a compound with
a 2
-morpholino-ethoxy side chain at the same position (e.g.,
compound G2 versus compound BAL16700; Table 1). This
indicates a flexibility for side chains at R1 which can be further
exploited.
These results are in line with those obtained with the B.
anthracis DHFR homology model developed on the basis of
the crystal structure of the DHFR from a TMP-resistant S.
aureus strain (10). For example, the different IC50 values of
compounds G1, C2, and BAL16796 reflect well the expected
alteration of the preference for substituents at position R2. Of
these three compounds, compound BAL16796 showed the best
affinity and compound C2 showed the poorest affinity in S.
aureus (data not shown). According to molecular modeling,
this ranking is changed in B. anthracis due to the favorable
interactions of the hydroxyl group of compound C2 and the
repulsive interactions of the carbonyl group of compound
BAL16796 with the Q30 (which replaced the K30 of S. aureus),
thus rendering compound C2 a better inhibitor than com-
pound BAL16796 of the B. anthracis DHFR (Table 1).
The model also helped to identify several residues which are
likely to contribute to the altered ligand-binding properties of
the B. anthracis DHFR. The mutations D28E and L6M appear
to affect mainly the diaminopyridine scaffold of the inhibitors,
whereas other mutations, in particular, S50A, K30Q, and
T37M, are likely to influence the selectivity for the R1 and R2
substituents.
The data obtained in this study show that the DHFR inhib-
itors tested have the potential to become clinically relevant
drugs. Optimization of the MIC, while keeping the excellent
selectivity for the bacterial enzyme, is a next goal. A chemistry
program will be guided by structural information to make the
proper modifications. The development of effective antimicro-
bials affecting this target in B. anthracis is particularly impor-
tant for the treatment of anthrax. Such a drug would generally
be welcomed as a contribution to address the problem of
infections caused by antibiotic-resistant bacteria.
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